Nurix Therapeutics announced an 83% objective response rate in CLL patients in a Phase 1a study of bexobrutideg, with a median progression-free survival of 22.1 months. Data from Phase 1b cohorts show higher response rates and longer progression-free survival at the 600 mg dose compared to the 200 mg dose. The drug was well tolerated, with a consistent safety profile. A Phase 2 trial is currently enrolling globally, and a webcast discussing the data will be held on December 8th. These results support the development of bexobrutideg as a promising therapeutic option for patients with B-cell malignancies.

Read more at GlobeNewswire: Nurix Therapeutics Presents New Data Demonstrating Durable,